Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.

AIMS To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with...

Descripción completa

Detalles Bibliográficos
Autores: Gimeno, Juan R, Olivotto, Iacopo, Rodríguez, Ana Isabel, Ho, Carolyn Y, Fernández, Adrián, Quiroga, Alejandro, Espinosa, Mari Angeles, Gómez-González, Cristina, Robledo, María, Tojal-Sierra, Lucas, Day, Sharlene M, Owens, Anjali, Barriales-Villa, Roberto, Larrañaga, Jose María, Rodríguez-Palomares, Jose, González-Del-Hoyo, Maribel, Piqueras-Flores, Jesús, Reza, Nosheen, Chumakova, Olga, Ashley, Euan A, Parikh, Victoria, Wheeler, Matthew, Jacoby, Daniel, Pereira, Alexandre C, Saberi, Sara, Helms, Adam S, Villacorta, Eduardo, Gallego-Delgado, María, de Castro, Daniel, Domínguez, Fernando, Ripoll-Vera, Tomás, Zorio-Grima, Esther, Sánchez-Martínez, José Carlos, García-Álvarez, Ana, Arbelo, Elena, Mogollón, María Victoria, Fuentes-Cañamero, María Eugenia, Grande, Elias, Peña, Carlos, Monserrat, Lorenzo, Lakdawala, Neal K
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/16855
Acceso en línea:http://hdl.handle.net/20.500.12105/16855
Access Level:acceso abierto
Palabra clave:COVID-19
Cardiomyopathy, Hypertrophic
Ventricular Dysfunction, Left
Atrial Fibrillation
Humans
Male
Adult
Middle Aged
Aged
Female
SARS-CoV-2
Registries
id ES_769d5dc0883032ee00872cd2b0abae1b
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/16855
network_acronym_str ES
network_name_str España
repository_id_str
spelling Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.Gimeno, Juan ROlivotto, IacopoRodríguez, Ana IsabelHo, Carolyn YFernández, AdriánQuiroga, AlejandroEspinosa, Mari AngelesGómez-González, CristinaRobledo, MaríaTojal-Sierra, LucasDay, Sharlene MOwens, AnjaliBarriales-Villa, RobertoLarrañaga, Jose MaríaRodríguez-Palomares, JoseGonzález-Del-Hoyo, MaribelPiqueras-Flores, JesúsReza, NosheenChumakova, OlgaAshley, Euan AParikh, VictoriaWheeler, MatthewJacoby, DanielPereira, Alexandre CSaberi, SaraHelms, Adam SVillacorta, EduardoGallego-Delgado, Maríade Castro, DanielDomínguez, FernandoRipoll-Vera, TomásZorio-Grima, EstherSánchez-Martínez, José CarlosGarcía-Álvarez, AnaArbelo, ElenaMogollón, María VictoriaFuentes-Cañamero, María EugeniaGrande, EliasPeña, CarlosMonserrat, LorenzoLakdawala, Neal KCOVID-19Cardiomyopathy, HypertrophicVentricular Dysfunction, LeftAtrial FibrillationHumansMaleAdultMiddle AgedAgedFemaleSARS-CoV-2RegistriesAIMS To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). CONCLUSIONS Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.Wiley20232023-12-2020222022-08-0120222022-08-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/16855reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución-CompartirIgual 4.0 Internacionalhttp://creativecommons.org/licenses/by-sa/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/168552026-06-12T12:43:37Z
dc.title.none.fl_str_mv Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
title Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
spellingShingle Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
Gimeno, Juan R
COVID-19
Cardiomyopathy, Hypertrophic
Ventricular Dysfunction, Left
Atrial Fibrillation
Humans
Male
Adult
Middle Aged
Aged
Female
SARS-CoV-2
Registries
title_short Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
title_full Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
title_fullStr Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
title_full_unstemmed Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
title_sort Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry.
dc.creator.none.fl_str_mv Gimeno, Juan R
Olivotto, Iacopo
Rodríguez, Ana Isabel
Ho, Carolyn Y
Fernández, Adrián
Quiroga, Alejandro
Espinosa, Mari Angeles
Gómez-González, Cristina
Robledo, María
Tojal-Sierra, Lucas
Day, Sharlene M
Owens, Anjali
Barriales-Villa, Roberto
Larrañaga, Jose María
Rodríguez-Palomares, Jose
González-Del-Hoyo, Maribel
Piqueras-Flores, Jesús
Reza, Nosheen
Chumakova, Olga
Ashley, Euan A
Parikh, Victoria
Wheeler, Matthew
Jacoby, Daniel
Pereira, Alexandre C
Saberi, Sara
Helms, Adam S
Villacorta, Eduardo
Gallego-Delgado, María
de Castro, Daniel
Domínguez, Fernando
Ripoll-Vera, Tomás
Zorio-Grima, Esther
Sánchez-Martínez, José Carlos
García-Álvarez, Ana
Arbelo, Elena
Mogollón, María Victoria
Fuentes-Cañamero, María Eugenia
Grande, Elias
Peña, Carlos
Monserrat, Lorenzo
Lakdawala, Neal K
author Gimeno, Juan R
author_facet Gimeno, Juan R
Olivotto, Iacopo
Rodríguez, Ana Isabel
Ho, Carolyn Y
Fernández, Adrián
Quiroga, Alejandro
Espinosa, Mari Angeles
Gómez-González, Cristina
Robledo, María
Tojal-Sierra, Lucas
Day, Sharlene M
Owens, Anjali
Barriales-Villa, Roberto
Larrañaga, Jose María
Rodríguez-Palomares, Jose
González-Del-Hoyo, Maribel
Piqueras-Flores, Jesús
Reza, Nosheen
Chumakova, Olga
Ashley, Euan A
Parikh, Victoria
Wheeler, Matthew
Jacoby, Daniel
Pereira, Alexandre C
Saberi, Sara
Helms, Adam S
Villacorta, Eduardo
Gallego-Delgado, María
de Castro, Daniel
Domínguez, Fernando
Ripoll-Vera, Tomás
Zorio-Grima, Esther
Sánchez-Martínez, José Carlos
García-Álvarez, Ana
Arbelo, Elena
Mogollón, María Victoria
Fuentes-Cañamero, María Eugenia
Grande, Elias
Peña, Carlos
Monserrat, Lorenzo
Lakdawala, Neal K
author_role author
author2 Olivotto, Iacopo
Rodríguez, Ana Isabel
Ho, Carolyn Y
Fernández, Adrián
Quiroga, Alejandro
Espinosa, Mari Angeles
Gómez-González, Cristina
Robledo, María
Tojal-Sierra, Lucas
Day, Sharlene M
Owens, Anjali
Barriales-Villa, Roberto
Larrañaga, Jose María
Rodríguez-Palomares, Jose
González-Del-Hoyo, Maribel
Piqueras-Flores, Jesús
Reza, Nosheen
Chumakova, Olga
Ashley, Euan A
Parikh, Victoria
Wheeler, Matthew
Jacoby, Daniel
Pereira, Alexandre C
Saberi, Sara
Helms, Adam S
Villacorta, Eduardo
Gallego-Delgado, María
de Castro, Daniel
Domínguez, Fernando
Ripoll-Vera, Tomás
Zorio-Grima, Esther
Sánchez-Martínez, José Carlos
García-Álvarez, Ana
Arbelo, Elena
Mogollón, María Victoria
Fuentes-Cañamero, María Eugenia
Grande, Elias
Peña, Carlos
Monserrat, Lorenzo
Lakdawala, Neal K
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv COVID-19
Cardiomyopathy, Hypertrophic
Ventricular Dysfunction, Left
Atrial Fibrillation
Humans
Male
Adult
Middle Aged
Aged
Female
SARS-CoV-2
Registries
topic COVID-19
Cardiomyopathy, Hypertrophic
Ventricular Dysfunction, Left
Atrial Fibrillation
Humans
Male
Adult
Middle Aged
Aged
Female
SARS-CoV-2
Registries
description AIMS To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events. METHODS AND RESULTS Three hundred and five patients [age 56.6 ± 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.0229}, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600). CONCLUSIONS Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-08-01
2022
2022-08-01
2023
2023-12-20
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12105/16855
url http://hdl.handle.net/20.500.12105/16855
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-CompartirIgual 4.0 Internacional
http://creativecommons.org/licenses/by-sa/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Atribución-CompartirIgual 4.0 Internacional
http://creativecommons.org/licenses/by-sa/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411063505616896
score 15,812429